

20 November 2025

Results of Annual General Meeting

Botanix Pharmaceuticals Ltd (ASX: BOT, “Botanix” or “the Company”) wishes to advise pursuant to Listing Rule 3.13.2 that all resolutions presented at the 2025 Annual General Meeting of Shareholders held today were carried out by a poll. Shareholders passed all resolutions, with the exception of Resolution 1 relating to the approval of the Remuneration Report.

In accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act, the Company advises that details of the resolutions and the votes received in respect of each resolution are set out in the attached summary.

Release authorised by the Board of Directors.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which has received FDA approval for its lead product *Sofdra* for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications
Botanix Pharmaceuticals
: +61 8 6555 2945
investors@botanixpharma.com

Investor enquiries

Hannah Howlett
WE Communications
P: +61 450 648 064
hhowlett@we-worldwide.com

Media enquiries

Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital

Disclosure of Proxy Votes

Botanix Pharmaceuticals Limited

Annual General Meeting

Thursday, 20 November 2025



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

| Resolution | Decided by Show of Hands (S) or Poll (P) | Total Number of Proxy Votes exercisable by proxies validly appointed | Proxy Votes | | | | Poll Results (if applicable) | | | Results |
|--|--|--|-----------------------|-----------------------|------------|--------------------|------------------------------|-----------------------|------------|---------|
| | | | FOR | AGAINST | ABSTAIN | PROXY'S DISCRETION | FOR | AGAINST | ABSTAIN | OUTCOME |
| 1 Non Binding Resolution to adopt Remuneration Report | P | 582,632,553 | 151,382,524 25.98% | 429,064,081 73.64% | 19,302,290 | 2,185,948 0.38% | 156,995,578 26.79% | 429,064,081 73.21% | 19,302,290 | - |
| 2 Re-election of Dr Patricia Walker as a Director | P | 633,418,738 | 565,938,173 89.35% | 63,013,243 9.95% | 5,683,985 | 4,467,322 0.71% | 573,832,601 90.11% | 63,013,243 9.89% | 5,683,985 | Carried |
| 3 Re-election of Mr Daniel Sharp as a Director | P | 611,333,365 | 552,882,051 90.44% | 54,183,992 8.86% | 27,769,358 | 4,267,322 0.70% | 560,576,479 91.19% | 54,183,992 8.81% | 27,769,358 | Carried |
| 4 Re-election of Dr Stewart Washer as a Director | P | 629,786,262 | 391,141,793 62.11% | 234,377,147 37.22% | 9,316,461 | 4,267,322 0.68% | 398,836,221 62.99% | 234,377,147 37.01% | 9,316,461 | Carried |
| 5 Ratification of issue of Placement Shares to institutional and sophisticated investors | P | 271,628,315 | 232,749,918 85.69% | 36,258,058 13.35% | 10,459,102 | 2,620,339 0.96% | 237,284,929 86.75% | 36,258,058 13.25% | 10,459,102 | Carried |

